Nanomedicine for colon-targeted drug delivery: strategies focusing on inflammatory bowel disease and colon cancer.

Nanomedicine (London, England) Pub Date : 2024-06-20 Epub Date: 2024-06-10 DOI:10.1080/17435889.2024.2350356

Ankaj Kumar, Klaudi K Vaiphei, Naveen Singh, Sri Pada Datta Chigurupati, Shivani Rai Paliwal, Rishi Paliwal, Arvind Gulbake

{"title":"Nanomedicine for colon-targeted drug delivery: strategies focusing on inflammatory bowel disease and colon cancer.","authors":"Ankaj Kumar, Klaudi K Vaiphei, Naveen Singh, Sri Pada Datta Chigurupati, Shivani Rai Paliwal, Rishi Paliwal, Arvind Gulbake","doi":"10.1080/17435889.2024.2350356","DOIUrl":null,"url":null,"abstract":"<p><p>The nanostructured drug-delivery systems for colon-targeted drug delivery are a promising field of research for localized diseases particularly influencing the colonic region, in other words, ulcerative colitis, Crohn's disease, and colorectal cancer. There are various drug-delivery approaches designed for effective colonic disease treatment, including stimulus-based formulations (enzyme-triggered systems, pH-sensitive systems) and magnetically driven drug-delivery systems. In addition, targeted drug delivery by means of overexpressed receptors also offers site specificity and reduces drug resistance. It also covers GI tract-triggered emulsifying systems, nontoxic plant-derived nanoformulations as advanced drug-delivery techniques as well as nanotechnology-based clinical trials toward colonic diseases. This review gives insight into advancements in colon-targeted drug delivery to meet site specificity or targeted drug-delivery requirements.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":"19 15","pages":"1347-1368"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11318742/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17435889.2024.2350356","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/10 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

The nanostructured drug-delivery systems for colon-targeted drug delivery are a promising field of research for localized diseases particularly influencing the colonic region, in other words, ulcerative colitis, Crohn's disease, and colorectal cancer. There are various drug-delivery approaches designed for effective colonic disease treatment, including stimulus-based formulations (enzyme-triggered systems, pH-sensitive systems) and magnetically driven drug-delivery systems. In addition, targeted drug delivery by means of overexpressed receptors also offers site specificity and reduces drug resistance. It also covers GI tract-triggered emulsifying systems, nontoxic plant-derived nanoformulations as advanced drug-delivery techniques as well as nanotechnology-based clinical trials toward colonic diseases. This review gives insight into advancements in colon-targeted drug delivery to meet site specificity or targeted drug-delivery requirements.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

用于结肠靶向给药的纳米医学：以炎症性肠病和结肠癌为重点的战略。

用于结肠靶向给药的纳米结构给药系统是一个前景广阔的研究领域，可用于治疗特别影响结肠区域的局部疾病，即溃疡性结肠炎、克罗恩病和结肠直肠癌。目前有多种有效治疗结肠疾病的给药方法，包括基于刺激的制剂（酶触发系统、pH 值敏感系统）和磁驱动给药系统。此外，通过过表达受体进行靶向给药还能提供部位特异性并减少耐药性。该综述还涉及消化道触发乳化系统、作为先进给药技术的无毒植物纳米制剂以及针对结肠疾病的纳米技术临床试验。本综述深入探讨了结肠靶向给药的进展，以满足部位特异性或靶向给药的要求。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Nanomedicine (London, England)

自引率

0.00%

发文量

期刊最新文献

Ultrasmall solid lipid nanoparticles as a potential innovative delivery system for a drug combination against glioma. Advances in Alzheimer's disease control approaches via carbon nanotubes. CD133-targeted afatinib nanomicelles for enhanced lung cancer theranostics. Correction. The emergence of inhalable RNA therapeutics and challenges faced - where to from here?